Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera

Abstract: Extracellular proteolytic enzymes of the urokinase‐type plasminogen activator (uPA) system and the family of metalloproteases play a crucial role in the matrix degradation and tissue remodelling processes characteristic of malignant disorders. The receptor for urokinase plasminogen activator (uPAR) serves to localise and intensify the action of uPA and is expressed on the surface of malignant as well as tumour stromal cells including fibroblasts. A soluble form of uPAR (suPAR) cleaved from its glycosyl‐phosphatidylinositol anchor is detected in plasma from healthy individuals and increased levels of suPAR have been found in advanced malignancy, suggesting that suPAR may be a marker of extensive tissue remodelling. In an attempt to clarify whether suPAR might be a marker for bone marrow tissue remodelling we measured plasma suPAR levels in a patient cohort comprising 17 with myelofibrosis (MF), 17 with polycythaemia vera (PV), 15 with essential thrombocythaemia (ET), one with a transitional myeloproliferative disorder evolving from PV and 30 controls. Compared with controls suPAR levels were significantly higher in the patients (P < 0.0001) (median 3.35 vs. 2.32 µg L−1). Moreover, in subgroup analyses including patients with MF, PV, and ET, respectively, suPAR levels differed significantly with the highest levels found in patients with MF and PV (MF vs. PV vs. ET; P = 0.0003). When comparing suPAR levels of the individual patient subgroups with controls, only suPAR levels of PV and MF patients were significantly increased (P < 0.0001). Sixty‐five percent of patients with PV and MF (22/34) had suPAR plasma values that were above the mean +2 standard deviations (SD) of controls. The concentration of suPAR was significantly correlated to plasma lactate dehydrogenase, thrombomodulin, and complex of tPA:PAI‐1 in the patients. There was no difference between patients and controls when comparing plasma uPA levels. Increased plasma suPAR levels in patients with chronic myeloproliferative disorders may reflect increased uPAR production in the bone marrow, leading to enhanced bone marrow remodelling.

[1]  M. Jensen,et al.  Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders , 2002, American journal of hematology.

[2]  M. Jensen,et al.  Increased circulating platelet–leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count , 2001, European journal of haematology.

[3]  K. Preissner,et al.  Urokinase receptor: a molecular organizer in cellular communication. , 2000, Current opinion in cell biology.

[4]  F. Wendling,et al.  Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. , 2000, Blood.

[5]  M. Jensen,et al.  Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders , 2000, British journal of haematology.

[6]  J. Palmblad,et al.  Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. , 2000, The American journal of pathology.

[7]  A. Tefferi.  Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.

[8]  M. Lübbert,et al.  Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. , 2000, Blood.

[9]  N. Brünner,et al.  The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. , 2000, Cancer research.

[10]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[11]  T. Takahara,et al.  Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. , 1999, Journal of hepatology.

[12]  G Murphy,et al.  Proteolysis and cell migration: creating a path? , 1999, Current opinion in cell biology.

[13]  N. Brünner,et al.  Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis , 1999, Annals of the rheumatic diseases.

[14]  H. Nielsen,et al.  Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. , 1999, Journal of the National Cancer Institute.

[15]  S. Mustjoki,et al.  Blast Cell-surface and Plasma Soluble Urokinase Receptor in Acute Leukemia Patients: Relationship to Classification and Response to Therapy , 1999, Thrombosis and Haemostasis.

[16]  B. Nielsen,et al.  Cancer invasion and tissue remodeling‐cooperation of protease systems and cell types , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[17]  N. Brünner,et al.  Complexes between urokinase‐type plasminogen activator and its receptor in blood as determined by enzyme‐linked immunosorbent assay , 1998, International journal of cancer.

[18]  D. Lison,et al.  Role of urokinase in the fibrogenic response of the lung to mineral particles. , 1998, American journal of respiratory and critical care medicine.

[19]  S. Rafii,et al.  Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. , 1998, Journal of immunology.

[20]  T. Plesner,et al.  Structure, Function and Expression on Blood and Bone Marrow Cells of the Urokinase‐Type Plasminogen Activator Receptor, uPAR , 1997, Stem cells.

[21]  H. Nielsen,et al.  ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. , 1997, Clinical chemistry.

[22]  D. Berger,et al.  Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. , 1997, Surgery.

[23]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[24]  L. Zanetta,et al.  Control of type IV collagenase activity by components of the urokinase–plasmin system: a regulatory mechanism with cell‐bound reactants , 1997, The EMBO journal.

[25]  K. Preissner,et al.  The Urokinase-receptor (CD87) Is Expressed in Cells of the Megakaryoblastic Lineage , 1997, Thrombosis and Haemostasis.

[26]  G. Raghu,et al.  Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs. , 1996, American journal of respiratory cell and molecular biology.

[27]  H. Ohtani,et al.  Expression of urokinase receptor in various stromal‐cell populations in human colon cancer: Immunoelectron microscopical analysis , 1995, International journal of cancer.

[28]  T. McCaffrey,et al.  THP‐1 macrophage membrane‐bound plasmin activity is up‐regulated by transforming growth factor‐β1 via increased expression of urokinase and the urokinase receptor , 1995 .

[29]  H. Johnsen,et al.  Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. , 1994, American journal of clinical pathology.

[30]  P. Rameshwar,et al.  Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta. , 1994, Journal of immunology.

[31]  S. Chevillard,et al.  Transforming growth factor‐β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis , 1994, British journal of haematology.

[32]  D. Rifkin,et al.  Requirement for receptor‐bound urokinase in plasmin‐dependent cellular conversion of latent TGF‐β to TGF‐β , 1994 .

[33]  L. Kirkeby,et al.  Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer , 1994, Histopathology.

[34]  N. Brünner,et al.  Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. , 1993, Cancer research.

[35]  S. Moestrup,et al.  Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. , 1992, The Journal of biological chemistry.

[36]  J. Reilly,et al.  Pathogenesis of idiopathic myelofibrosis: role of growth factors. , 1992, Journal of clinical pathology.

[37]  E. Wilson,et al.  Regulation of proteolytic activity in human bone marrow stromal cells by basic fibroblast growth factor, interleukin-1, and transforming growth factor beta. , 1992, Blood.

[38]  L. Lund,et al.  Urokinase‐receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells. , 1991, The EMBO journal.

[39]  M. Cubellis,et al.  Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1. , 1990, The EMBO journal.

[40]  J. Laszlo,et al.  Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. , 1986, Seminars in hematology.

[41]  J. Goldberg,et al.  Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. , 1986, Seminars in hematology.

[42]  K. Preissner,et al.  Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. , 1998, Blood.

[43]  G. von Minckwitz,et al.  Transforming growth factor-beta stimulates urokinase expression in tumor-associated macrophages of the breast. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[44]  L. Kirkeby,et al.  Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. , 1991, The American journal of pathology.

[45]  P. Dombernowsky,et al.  Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. , 1988, The Journal of laboratory and clinical medicine.